830 Development of a new procurement protocol for human pancreas aimed at the generation of decellularized pancreatic scaffolds
Wednesday November 18, 2015 from 15:30 to 17:00
Room 111-112

Talita S. Carmo, Brazil

School of Medicine - Internal Medicine Department

NUCEL - Cell and Moleecular Therapy Center - University of São Paulo


Development of a new procurement protocol for human pancreas aimed at the generation of decellularized pancreatic scaffolds

Talita Carmo1, Marluce C. Mantovani1,2, Carlos Pantanali3, Igor L. Calil3, Vinícius R. Santos3, Maria Lúcia Corrêa-Gianella1,2, Mari Cleide Sogayar1,4.

1Cell and Molecular Therapy Center NUCEL/NETCEM - Intern al Medicine Department, Medical School, University of São Paulo, São Paulo, Brazil; 2Endocrinology Sector, Internal Medicine Department, Medical School, University of São Paulo, São Paulo, São Paulo, Brazil; 3. Liver Transplant Unit, Department of Gastroenterology, Clinical Hospital , University of São Paulo, São Paulo, Brazil; 4Chemistry Institute, Biochemistry Department, University of São Paulo, São Paulo, Brazil

Cellular Therapy for Unstable Diabetes Mellitus Type 1.

Currently, several attractive approaches are available for the treatment of Type 1 Diabetes mellitus (T1DM), a disease caused by the autoimmune destruction of pancreatic β cells, leading patients to require lifelong insulin therapy. Pancreatic islet transplantation appears as an attractive approach performed by only a few Centers around the World, which still considered as an experimental procedure, and which our group introduced in Brazil in 2002. Human islet isolation from brain-dead organ donors, and their proper purification and characterization requires a highly trained team and a special cGMP (Current Good Manufacturing Practices) facility, such as the 220 m2 Bioclean Rooms facility we hold at the University of São Paulo Cell and Molecular Therapy Center (NUCEL www.usp.br/nucel). In addition to islet transplantation, this facility allows isolation, purification, characterization and differentiation of stem cells, generation of iPSCs (Induced Pluripotent Stem Cells)and production of biopharmaceuticals under strict GMP conditions, developing technological innovations and scientific discoveries, thereby facilitating the implantation of cell and molecular therapy protocols. Recently, pancreatic bioengineering in Regenerative Medicine have been proposed as potential and powerful alternative therapeutic approaches. Human pancreas may be decellularized and the remaining bioscaffold, a skeleton of extracellular matrix (ECM), may provide the optimal microstructure and microenvironment for islets formation from cultured beta cells or stem cells differentiated in insulin-producing cells aiming at their  transplantation. Therefore, this bioscaffold may be used as an attractive 3D template for several studies aiming to restore pancreata´s dual function, namely: endocrine and exocrine. Using this expertise, our group designed a new procurement protocol, different from that used in the case of islets isolation, This protocol consists of discarding the pancreata head and cannulating the remaining organ by three different vias. The organ may be transported from the Surgical Center to the Bioclean facility in a Preservation Solution, instead of the mixture of Organ Preservation Solution plus Perfluorocarbon (PFC), as is currently used in islet the transplantation procurement. These protocol modifications improve the decellularization process by significantly saving time and financial resources. This new procurement protocol improves the pancreas decellularization process, maintaining the extracellular matrix structure, aiming to develop an alternative treatment for T1DM.

CNPq- Conselho Nacional de Desenvolvimento Científico e Tecnológico.


[1] Nanji SA, Shapiro AM.Diabetes, Obesity and Metabolism 2006; 8: 15-25.
[2] Gilbert, T.W., Sellaro, T.L., Badylak, S.F. Biomaterials, v. 27, p. 3675-3686. 2006.
[3] Mirmalek-Sani, S. H., G. Orlando, et al.Biomaterials, v.34, n.22, Jul, p.5488-95, 2013.
[4] De Carlo, E., S. Baiguera, et al. Int J Mol Med, v.25, n.2, Feb, p.195-202, 2010.
[5] Goh, S. K., S. Bertera, et al. Biomaterials, v.34, n.28, Sep, p.6760-72, 2013.

© 2018 Melbourne2015